In Reply We thank Deutch for his thoughtful response to our study,¹ in which we reported that the glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces body weight, improves glucose tolerance, and decreases systolic blood pressure in patients with schizophrenia receiving clozapine or olanzapine. Deutch correctly pointed out that GLP-1 receptor stimulation can dampen activation of the reward pathways (eg, reduction of cocaine-induced dopamine elevation²) and therefore suggested that a detailed assessment of liraglutide-induced psychiatric symptoms, particularly the so-called negative symptoms, such as anhedonia and blunted affect, should be performed before GLP-1 receptor agonists are used to counter antipsychotic-induced body weight gain and metabolic disturbances.

在答复中，我们感谢Deutch对我们的研究做出的深思熟虑的反应¹，其中我们报道了胰高血糖素样肽1（GLP-1）受体激动剂利拉鲁肽，可减轻体重，改善葡萄糖耐量并降低收缩压。精神分裂症患者接受氯氮平或奥氮平治疗。Deutch正确指出，GLP-1受体刺激可以抑制奖励途径的激活（例如，降低可卡因诱导的多巴胺升高²），因此建议在使用GLP-1受体激动剂对抗抗精神病药引起的体重增加和代谢紊乱。